The U.S. government will pay Eli Lilly $375 million to secure an initial supply of 300,000 vials of bamlanivimab, the pharma company’s experimental COVID-19 drug pending emergency approval by the Food and Drug Administration (FDA).
Eli Lilly on Wednesday announced the deal, adding that it expects to manufacture 1 million doses of bamlanivimab by the end of year, with 100,000 doses ready to ship for use around the world soon after authorization.
